Aripiprazole: A review of its use in the management of schizophrenia in adults

CNS Drugs

Volumn 26, Issue 2, 2012, Pages 155-183

  Croxtall, Jamie D ^a  

^a Adis ^*  (New Zealand)

Author keywords

Adis Drug Evaluations; Aripiprazole; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; CARBAMAZEPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; EFAVIRENZ; FLUOXETINE; HALOPERIDOL; ITRACONAZOLE; KETOCONAZOLE; NEVIRAPINE; OLANZAPINE; PAROXETINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; PROTEINASE INHIBITOR; QUINIDINE; RIFABUTIN; RIFAMPICIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; ZIPRASIDONE;

AGITATION; ANXIETY DISORDER; AREA UNDER THE CURVE; BINDING AFFINITY; COGNITION; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TOLERABILITY; HEADACHE; HUMAN; INSOMNIA; MAXIMUM PLASMA CONCENTRATION; MENTAL PATIENT; NAUSEA; NERVE CELL; NONHUMAN; OPEN STUDY; PHARMACOECONOMICS; POST HOC ANALYSIS; PREFRONTAL CORTEX; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; HUMANS; HYPERGLYCEMIA; PIPERAZINES; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; WEIGHT GAIN;

EID: 84856466357     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11208400-000000000-00000     Document Type: Review

References (110)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Press, 1994
2. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, "just the facts": 4. Clinical features and conceptualization. Schizophr Res 2009 May; 110 (1-3): 1-23
3. Green AL, Canuso CM, Brenner MJ, et al. Detection and management of comorbidity in patients with schizophrenia. Psychiatr Clin North Am 2003 Mar; 26 (1): 115-39 (Pubitemid 36384351)
4. Sharma T, Antonova L. Cognitive function in schizophrenia: deficits, functional consequences, and future treatment. Psychiatr Clin North Am 2003 Mar; 26 (1): 25-40 (Pubitemid 36384346)
5. Falkai P, Wobrock T, Lieberman J, et al.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia: part 1. Acute treatment of schizophrenia. World J Biol Psychiatry 2005; 6 (3): 132-91
6. Miller DD. Schizophrenia: its etiology and impact. Pharmacotherapy 1996 Jan 28; 16 (1 Pt 2): 2-5
7. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response froma first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999 Mar; 56 (3): 241-7 (Pubitemid 29125132)
8. Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull 2004; 30 (2): 279-93 (Pubitemid 38828535)
9. National Institute for Clinical Excellence. Schizophrenia: the NICE guideline on core interventions in the treatment and management of schizophrenia in adults primary and secondary care (updated edition) [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/CG82FullGuideline.pdf [Accessed 2100 Oct 12]
10. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009 Jan 3; 373 (9657): 31-41
11. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007; 21 (11): 911-36 (Pubitemid 47557106)
12. Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2004; 64 (15): 1715-36 (Pubitemid 39128008)
13. Bristol-Myers Squibb Company and Otsuka America Pharmaceutical I. Abilify-(aripiprazole) tablets: US prescribing information [online]. Available from URL: http://www.abilify.com [Accessed 2011 Aug 17]
14. European Medicines Agency. Abilify tablets: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en- GB/document-library/EPAR-Product-Information/human/000471/WC5000201 70.pdf [Accessed 2011 Aug 17]
15. Otsuka Pharmaceutical Co. Ltd. Otsuka's antipsychotic Abilify-is approved in Japan [online]. Available from URL: http://www.otsuka.co.jp/en/release/2006/ 0125-01. html [Accessed 2011 Oct 6]
16. Wood M, Reavill C. Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Expert Opin Invest Drugs 2007; 16 (6): 771-5 (Pubitemid 46882352)
17. Kikuchi T, Tottori K, Uwahodo Y, et al. 7-(4-[4-(2,3-dichlorophenyl)-1- piperazinyl]butyloxy)-3,4-dihydro-2(1H)-qui nolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 1995 Jul; 274 (1): 329-36
18. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002 Jul; 302 (1): 381-9 (Pubitemid 34680462)
19. Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002 Apr; 441 (3): 137-40 (Pubitemid 34626163)
20. Grunder G, Fellows C, Janouschek H, et al. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. Am J Psychiatry 2008 Aug; 165 (8): 988-95
21. Grunder G, Kungel M, Ebrecht M, et al. Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia. Pharmacopsychiatry 2006 Feb; 39 Suppl. 1: S21-5 (Pubitemid 43357102)
22. Reist C, Albers LJ, Marder SR, et al. A candidate pathway strategy for integration of pharmacogenomic components of variability in antipsychotic treatment outcomes: a focus on aripiprazole. Curr Pharmacogenomics 2005; 3 (4): 305-17 (Pubitemid 41723560)
23. Horacek J, Bubenikova-Valesova V, Kopecek M, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006; 20 (5): 389-409 (Pubitemid 43763739)
24. Dahan L, Husum H, Mnie-Filali O, et al. Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour. J Psychopharmacol 2009; 23 (2): 177-89
25. Momiyama T, Amano T, Todo N, et al. Inhibition by a putative antipsychotic quinolinone derivative (OPC-14597) of dopaminergic neurons in the ventral tegmental area. Eur J Pharmacol 1996 Aug; 310 (1): 1-8 (Pubitemid 26284249)
26. Matsubayashi H, Amano T, Sasa M. Inhibition by aripiprazole of dopaminergic inputs to striatal neurons from substantia nigra. Psychopharmacology (Berl) 1999 Sep; 146 (2): 139-43 (Pubitemid 29474205)
27. Nakai S, Hirose T, Mori T, et al. The effect of aripiprazole on prepulse inhibition of the startle response in normal and hyperdopaminergic states in rats. Int J Neurosci 2008 Jan; 118 (1): 39-57 (Pubitemid 350175300)
28. Ishii D, Matsuzawa D, Kanahara N, et al. Effects of aripiprazole on MK-801-induced prepulse inhibition deficits and mitogen-activated protein kinase signal transduction pathway. Neurosci Lett 2010; 471 (1): 53-7
29. Cosi C, Waget A, Rollet K, et al. Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation. Brain Res 2005 May; 1043 (1-2): 32-41 (Pubitemid 40603369)
30. Abekawa T, Ito K, Nakagawa S, et al. Effects of aripiprazole and haloperidol on progression to schizophrenia-like behavioural abnormalities and apoptosis in rodents. Schizophr Res 2011 Jan; 125 (1): 77-87
31. Yang TT, Wang SJ. Aripiprazole and its human metabolite OPC14857 reduce, through a presynaptic mechanism, glutamate release in rat prefrontal cortex: possible relevance to neuroprotective interventions in schizophrenia. Synapse 2008 Nov; 62 (11): 804-18
32. Nakai S, Hirose T, Uwahodo Y, et al. Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone. Eur J Pharmacol 2003 Jul 4; 472 (1-2): 89-97 (Pubitemid 36830995)
33. Yokoi F, Grunder G, Biziere K, et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C] raclopride. Neuropsychopharmacology 2002 Aug; 27 (2): 248-59 (Pubitemid 34692591)
34. Stip E. Cognition, schizophrenia and the effect of antipsychotics [in French]. Encephale 2006 May 30; 32 (3 Pt 1): 341-50 (Pubitemid 43941530)
35. Kern RS, Green MF, Cornblatt BA, et al. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology (Berl) 2006; 187 (3): 312-20 (Pubitemid 44079923)
36. Riedel M, Schennach-Wolff R, Musil R, et al. Neurocognition and its influencing factors in the treatment of schizophrenia-effects of aripiprazole, olanzapine, quetiapine and risperidone. Hum Psychopharmacol 2010 Mar; 25 (2): 116-25
37. Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 2004; 44 (2): 179-87 (Pubitemid 38114317)
38. Boulton DW, Kollia G, Mallikaarjun S, et al. Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia. Clin Pharmacokinet 2008; 47 (7): 475-85 (Pubitemid 351861959)
39. Suzuki T, Mihara K, Nakamura A, et al. Effects of the cyp2d6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Ther Drug Monit 2011; 33 (1): 21-4
40. Castberg I, Spigset O. Effects of comedication on the serum levels of aripiprazole: evidence from a routine therapeutic drug monitoring service. Pharmacopsychiatry 2007; 40 (3): 107-10 (Pubitemid 46910381)
41. Nakamura A, Mihara K, Nagai G, et al. Pharmacokinetic and pharmacodynamic interactions between carbamazepine and aripiprazole in patients with schizophrenia. Ther Drug Monit 2009 Oct; 31 (5): 575-8
42. Citrome L, Josiassen R, Bark N, et al. Pharmacokinetics of aripiprazole and concomitant lithium and valproate. J Clin Pharmacol 2005 Jan; 45 (1): 89-93
43. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002 Sep; 63 (9): 763-71
44. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003 Jul; 60 (7): 681-90 (Pubitemid 36818630)
45. Cutler AJ, Marcus RN, Hardy SA, et al. The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia. CNS Spectr 2006 Sep; 11 (9): 691-702 (Pubitemid 44449654)
46. McEvoy JP, Daniel DG, Carson WH Jr, et al. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. J Psychiatr Res 2007 Dec; 41 (11): 895-905 (Pubitemid 47260697)
47. Marder SR, West B, Lau GS, et al. Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials. J Clin Psychiatry 2007 May; 68 (5): 662-8 (Pubitemid 46841848)
48. Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003 Sep; 64 (9): 1048-56 (Pubitemid 37158250)
49. Chan H-Y, Lin W-W, Lin S-K, et al. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial. J Clin Psychiatry 2007; 68 (1): 29-36 (Pubitemid 46220121)
50. Zimbroff D, Warrington L, Loebel A, et al. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. Int Clin Psychopharmacol 2007 Nov; 22 (6): 363-70 (Pubitemid 47530841)
51. Fleischhacker WW, McQuade RD, Marcus RN, et al. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry 2009 Mar 15; 65 (6): 510-7
52. Kane JM, Osuntokun O, Kryzhanovskaya LA, et al. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. J Clin Psychiatry 2009; 70 (4): 572-81
53. Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003 Nov 11; 6: 325-37 (Pubitemid 38146250)
54. Kane JM, Crandall DT, Marcus RN, et al. Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. Schizophr Res 2007 Sep; 95 (1-3): 143-50 (Pubitemid 47313629)
55. Tandon R, Marcus RN, Stock EG, et al. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophr Res 2006 May; 84 (1): 77-89 (Pubitemid 44255718)
56. Wolf J, Janssen F, Lublin H, et al. A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA). Curr Med Res Opin 2007 Oct; 23 (10): 2313-23 (Pubitemid 350033433)
57. Casey DE, Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 2003 Apr; 166 (4): 391-9 (Pubitemid 36469941)
58. Kim CY, Chung S, Lee JN, et al. A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder. Int Clin Psychopharmacol 2009 Jul; 24 (4): 181-8
59. Ryckmans V, Kahn JP, Modell S, et al. Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study. Pharmacopsychiatry 2009 May; 42 (3): 114-21
60. Kerwin R, Millet B, Herman E, et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients: Schizophrenia Trial of Aripiprazole (STAR) study. Eur Psychiatry 2007 Oct; 22 (7): 433-43 (Pubitemid 47600616)
61. Hanssens L, L'Italien G, Loze JY, et al. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC Psychiatry 2008; 8: 95
62. Taylor D, Hanssens L, Loze JY, et al. Preference of medicine and patient-reported quality of life in communitytreated schizophrenic patients receiving aripiprazole vs standard of care: results from the STAR study. Eur Psychiatry 2008 Aug; 23 (5): 336-43
63. Lee J-S, Chung S, Lee J-N, et al. Efficacy and tolerability of aripiprazole: a 26-week switching study from oral antipsychotics. Psychiatr Invest 2010; 7 (3): 189-95
64. MacFadden W, Ma Y-W, Thomas HJ, et al. A prospective study comparing the long-term effectiveness of injectable risperidone long-acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry (Edgemont) 2010; 7 (11): 23-31
65. Stroup TS, McEvoy JP, Ring KD, et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 2011 Jul 18; 168 (9): 947-56
66. Chrzanowski WK, Marcus RN, Torbeyns A, et al. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl) 2006 Dec; 189 (2): 259-66 (Pubitemid 44691547)
67. Kinon BJ, Stauffer VL, Kollack-Walker S, et al. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. J Clin Psychopharmacol 2008 Dec; 28 (6): 601-7
68. Andrezina R, Marcus RN, Oren DA, et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study. Curr Med Res Opin 2006 Nov; 22 (11): 2209-19 (Pubitemid 44789986)
69. Chang JS, AhnYM, Park HJ, et al.Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008 May; 69 (5): 720-31 (Pubitemid 351838681)
70. Kane JM, Correll CU, Goff DC, et al. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry 2009 Oct; 70 (10): 1348-57
71. Barbui C, Accordini S, Nose M, et al. Aripiprazole versus haloperidol in combination with clozapine for treatmentresistant schizophrenia in routine clinical care: a randomized, controlled trial. J Clin Psychopharmacol 2011; 31 (3): 266-73
72. Muscatello MRA, Bruno A, Pandolfo G, et al. Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Schizophr Res 2011; 127 (1-3): 93-9
73. Kane JM, Meltzer HY, Carson Jr WH, et al. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry 2007; 68 (2): 213-23 (Pubitemid 46362642)
74. Tandon R, Devellis RF, Han J, et al. Validation of the Investigator's Assessment Questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder. Psychiatry Res 2005 Sep 15; 136 (2-3): 211-21 (Pubitemid 41765219)
75. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003 Jun 1; 61 (2-3): 123-36 (Pubitemid 36513927)
76. McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004; 65 Suppl. 18: 47-56
77. Miller DD, Eudicone JM, Pikalov A, et al. Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis. J Clin Psychiatry 2007 Dec; 68 (12): 1901-6
78. Ulcickas Yood M, Delorenze G, Quesenberry CP Jr, et al. Epidemiologic study of aripiprazole use and the incidence of suicide events. Pharmacoepidemiol Drug Saf 2010 Nov; 19 (11): 1124-30
79. Newcomer JW, Campos JA, Marcus RN, et al. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry 2008; 69 (7): 1046-56 (Pubitemid 352031586)
80. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive summary of the third report of the National Cholesterol Education Program (NCEP). JAMA 2001; 285 (19): 2486-97
81. L'Italien GJ, Casey DE, Kan HJ, et al. Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo. J Clin Psychiatry 2007; 68 (10): 1510-6 (Pubitemid 350073397)
82. Ascher-Svanum H, Stensland MD, Peng X, et al. Costeffectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia. Curr Med Res Opin 2011 Jan; 27 (1): 115-22
83. Kane JM, Kim E, Kan HJ, et al. Comparative utility of aripiprazole and haloperidol in schizophrenia: post hoc analysis of two 52-week, randomized, controlled trials. Appl Health Econ Health Policy 2009; 7 (2): 109-19
84. Colombo GL, Caruggi M, Di MS, et al. An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatr Dis Treat 2008; 4 (5): 967-76
85. King D, Knapp M, Thomas P, et al. Cost-effectiveness analysis of aripiprazole vs standard-of-care in the management of community-treated patients with schizophrenia: STAR study. Curr Med Res Opin 2011 Feb; 27 (2): 365-74
86. Kasteng F, Eriksson J, Sennfalt K, et al. Metabolic effects and cost-effectiveness in aripiprazole versus olanzapine in schizophrenia and bipolar disorder. Acta Psychiatr Scand 2011 May 24
87. Barnett AH, MillarHL, Loze JY, et al.UKcost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STARstudy). Eur Arch Psychiatry Clin Neurosci 2009 Jun; 259 (4): 239-47
88. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Second edition [online]. Available from URL: http://www.psych.org [Accessed 2004 Mar 25]
89. Oehl M, Hummer M, Fleischhacker WW. Compliance with antipsychotic treatment. Acta Psychiatr Scand Suppl 2000; (407): 83-6 (Pubitemid 32115754)
90. Patel M, Taylor M, David A. Antipsychotic long-acting injections: mind the gap. Br J Psychiatry Suppl 2009; 52: S1-4
91. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 Sep 22; 353 (12): 1209-23 (Pubitemid 41345943)
92. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998 Feb; 49 (2): 196-201 (Pubitemid 28071427)
93. Buckley PF, Wirshing DA, Bhushan P, et al. Lack of insight in schizophrenia: impact on treatment adherence. CNS Drugs 2007; 21 (2): 129-41
94. Citrome L. Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection. Patient Prefer Adherence 2009; 3: 345-55
95. Marder SR, Essock SM, Miller AL, et al. The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophr Bull 2002; 28 (1): 5-16 (Pubitemid 34534746)
96. Thomas P, Alptekin K, Gheorghe M, et al. Management of patients presenting with acute psychotic episodes of schizophrenia. CNS Drugs 2009; 23 (3): 193-212
97. Haupt DW. Differential metabolic effects of antipsychotic treatments. Eur Neuropsychopharmacol 2006 Sep; 16 Suppl. 3: S149-55 (Pubitemid 44175821)
98. Mackin P, Bishop DR, Watkinson HM. A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients. BMC Psychiatry 2007; 7: 28
99. Masand PS, Culpepper L, Henderson D, et al. Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to appropriate atypical antipsychotic utilization. CNS Spectr 2005 Oct; 10 (10): suppl14 1-15 (Pubitemid 41531972)
100. Stauffer V, Ascher-Svanum H, Liu L, et al. Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials. BMC Psychiatry 2009; 9: 13
101. Shen C, Chen SF, Chen CH, et al. Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients. J Psychiatr Res 2009 Mar; 43 (6): 600-6
102. Pae CU, Chiesa A, Serretti A. Influence of DAOA gene variants on antipsychotic response after switch to aripiprazole. Psychiatry Res 2010 Jul 30; 178 (2): 430-2
103. Chen SF, Shen YC, Chen CH. HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients. Psychopharmacology (Berl) 2009 Aug; 205 (2): 285-92
104. Kwon JS, Kim E, KangDH, et al. Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole. Eur Neuropsychopharmacol 2008 Dec; 18 (12): 897-907
105. Pae CU, Chiesa A, Mandelli L, et al. No influence of DTNBP1 polymorphisms on the response to aripiprazole. Neuropsychobiology 2010; 62 (4): 245-9
106. Pae CU, Chiesa A, Mandelli L, et al. No influence of FAT polymorphisms in response to aripiprazole. J Hum Genet 2010 Jan; 55 (1): 32-6
107. Chen SF, Shen YC, Chen CH. Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors. Prog Neuropsychopharmacol Biol Psychiatry 2009 Apr 30; 33 (3): 470-4
108. Serretti A, Pae CU, Chiesa A, et al. Influence of TAAR6 polymorphisms on response to aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry 2009 Aug 1; 33 (5): 822-6
109. Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010 Jan; 36 (1): 71-93
110. Bergmann F, Zacher A, Nass A, et al. Psychosocial functioning in patients with schizophrenia treated with aripiprazole: an office-based real-world setting. Results from the German post-marketing surveillance study. Pharmacopsychiatry 2009 May; 42 (3): 101-8